Balanced Rock Investment Advisors LLC Increases Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Balanced Rock Investment Advisors LLC increased its stake in scPharmaceuticals Inc. (NASDAQ:SCPH) by 8.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 70,362 shares of the company’s stock after buying an additional 5,612 shares during the period. Balanced Rock Investment Advisors LLC’s holdings in scPharmaceuticals were worth $249,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its position in scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after acquiring an additional 3,101 shares during the period. Legato Capital Management LLC purchased a new stake in shares of scPharmaceuticals during the 4th quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of scPharmaceuticals in the 4th quarter worth approximately $38,000. Virtu Financial LLC purchased a new position in scPharmaceuticals in the third quarter valued at approximately $46,000. Finally, Wells Fargo & Company MN grew its holdings in scPharmaceuticals by 110.5% during the fourth quarter. Wells Fargo & Company MN now owns 18,407 shares of the company’s stock valued at $65,000 after purchasing an additional 9,663 shares during the period. 89.52% of the stock is owned by hedge funds and other institutional investors.

scPharmaceuticals Stock Up 0.8 %

SCPH opened at $2.57 on Friday. scPharmaceuticals Inc. has a 12 month low of $1.94 and a 12 month high of $5.65. The company has a market cap of $129.23 million, a PE ratio of -1.35 and a beta of 0.38. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The company has a 50 day moving average of $2.95 and a 200 day moving average of $3.44.

scPharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The firm had revenue of $12.15 million during the quarter, compared to analyst estimates of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. On average, sell-side analysts expect that scPharmaceuticals Inc. will post -1.53 EPS for the current year.

Analysts Set New Price Targets

SCPH has been the topic of several research reports. Maxim Group lowered their target price on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a report on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.